FMP

FMP

Enter

MDT - Medtronic plc

photo-url-https://images.financialmodelingprep.com/symbol/MDT.png

Medtronic plc

MDT

NYSE

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

89.25 USD

1.41 (1.58%)

Historical Prices

From:

To:

87.8587.988.288.588.889.189.2809:30 AM09:50 AM10:10 AM10:30 AM10:50 AM11:10 AM11:30 AM11:50 AM12:10 PM12:30 PM12:50 PM01:10 PM01:30 PM01:50 PM02:10 PM02:30 PM02:50 PM03:10 PM03:30 PM03:50 PM

About

ceo

Mr. Geoffrey Straub Martha

sector

Healthcare

industry

Medical - Devices

exchange

NYSE

Description

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The compan...

CIK

0001613103

ISIN

IE00BTN1Y115

CUSIP

G5960L103

Address

20 On Hatch

Phone

353 1 438 1700

Country

IE

Employee

95,000

IPO Date

May 2, 1973

Financial Statement

02B4B6B8B10B2024 Q22024 Q32024 Q42025 Q12025 Q2RevenueNet Income

Earnings

00.30.60.91.21.51.82023 Q12023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q4EPS Consensus

MDT Financial Summary

CIK

0001613103

Exchange

NYSE

Industry

Medical - Devices

Sector

Healthcare

CUSIP

G5960L103

ISIN

IE00BTN1Y115

Country

IE

Price

89.25

Beta

0.85

Volume Avg.

6.63M

Market Cap

114.44B

Shares

-

52-Week

75.96-92.68

DCF

95.98

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

27.29

P/B

-

Website

https://www.medtronic.com

Upgrades and Downgrades

Rating Distribution

Buy1

Hold0

Sell0

TheFly

15 days ago
Jan 8, 2025

Outperform

Outperform

Latest MDT News

Andrew Wynn

Nov 20, 2024

Medtronic's (NYSE:MDT) Latest Earnings Overview

Medtronic (NYSE:MDT) is a leading global healthcare technology company that specializes in medical devices and therapies. It operates in various segments, including cardiovascular, diabetes, and surgical technologies. Medtronic competes with other major players in the medical device industry, such as Johnson & Johnson and Boston Scientific. The company is known for its innovative products and solutions that improve patient outcomes. On November 19, 2024, Medtronic reported earnings per share (E...

The Motley Fool

Aug 26, 2024

This Is Great News for Medtronic, but Is It Time to Buy the ...

Medtronic delivered a strong first-quarter earnings report. The company benefits from continued market adoption of several new product launches over the past year.

Seeking Alpha

Aug 25, 2024

Medtronic: Is The Company Back?

Medtronic faced challenges, including poor focus, lack of innovation, and COVID-19 impact, leading to share price stagnation since 2018. Despite recent improvements in performance, Medtronic remains undervalued with solid competitive advantages and a promising dividend streak. The company's focus on innovation, strong market position, and dividend growth potential make it a long-term buy for conservative investors.

MarketBeat

Aug 23, 2024

Diabetes and Neuro Products Ignite Medtronic's Q1 Earnings R...

Shares of medical device manufacturer Medtronic PLC NYSE: MDT are down about 35% from their highs of roughly three years ago, but promising results from the company's first quarter of fiscal 2025, which ended July 26, could help to drive renewed upward momentum. Specifically, Medtronic's diabetes and neuromodulation products may be poised for breakout growth, and the company's up-and-coming products in various stages of development offer promise as well.

Forbes

Aug 22, 2024

What's Next For Medtronic Stock After An Upbeat Q1?

Medtronic (NYSE: MDT) recently reported its Q1 fiscal 2025 results (fiscal ends in April), with revenues and earnings exceeding our estimates. The company reported revenue of $7.9 billion and adjusted earnings of $1.23 per share, compared to our estimates of $7.9 billion and $1.21, respectively.

Zacks Investment Research

Aug 21, 2024

Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look a...

Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CNBC Television

Aug 20, 2024

Medtronic CEO: Strong single-digit earnings ahead as forex i...

Geoff Martha, Medtronic CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, where the company's business is toughest, and much more.

Zacks Investment Research

Aug 20, 2024

Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed

Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep